Abstract:Key PointsPerhaps the most well-replicated biological finding in post-traumatic stress disorder (PTSD) is higher autonomic (heart rate and skin conductance) and facial electromyography responding during internal, mental imagery of the traumatic event and upon exposure to external, trauma-related cues.Higher heart rate responding to sudden loud tones in PTSD probably reflects an acquired sensitization of the nervous system.Diminished volumes of the hippocampus and anterior cingulate cortex are the most frequently replicated neuroanatomic findings in patients with PTSD. These do not appear to be fully explained by comorbid conditions such as substance abuse and depression.Some evidence exists to support both pre-existing vulnerability and neurotoxicity as origins of brain volume reductions in PTSD. On the basis of present data, it is going too far to say that stress damages the brain, but there is no doubt that it changes it.Functional neuroimaging studies suggest that the amygdala and dorsal anterior cingulate cortex are hyper(re)active, whereas the ventral medial prefrontal cortex is hypo(re)active, in PTSD. These abnormalities are likely to underlie the attentional bias towards threat, impaired emotion regulation and persistence of fear memories in this disorder.The classic model of stress based on chronic hyperactivity of the hypothalamus–pituitary–adrenal cortical axis does not characterize PTSD.A number of neurotransmitters and neuroendocrinological factors interact to influence PTSD risk, symptom profiles and severity. These factors vary across individuals owing to genetic and epigenetic factors, as well as within individuals over time in response to environmental influences, including exposure to psychological trauma.As with other mental disorders, genetic vulnerability to PTSD is likely to involve the sum of contributions from multiple alleles, each with small effects.The full range of molecular genetic factors, which include genotype, methylation, histone deacetylation and gene expression, probably influence or accompany the development of PTSD. However, at this time, there are no definitive findings for any one gene or gene system in the aetiology of the disorder.Animal models have identified important molecular pathways that are likely to contribute to the pathophysiology of PTSD and may constitute promising therapeutic targets.

PTSD and Current Translational Research

Neuromodulation Strategies in Post-Traumatic Stress Disorder: From Preclinical Models to Clinical Applications

PTSD biomarkers: Neuroendocrine signaling to epigenetic variants

Neurobiology and Treatment of Posttraumatic Stress Disorder

PTSD: Past, present and future implications for China

A Neuroanatomic and Pathophysiologic Framework for Novel Pharmacological Approaches to the Treatment of Post-traumatic Stress Disorder

Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits

Biological studies of post-traumatic stress disorder

Multi-omic biomarker identification and validation for diagnosing warzone-related post-traumatic stress disorder

The Etiology and Pathogenesis of Post-Traumatic Stress Disorder

PTSD: Evidence-Based Psychotherapy and Emerging Treatment Approaches

The neural circuits and molecular mechanisms underlying fear dysregulation in posttraumatic stress disorder

Post‐traumatic stress disorder: a state‐of‐the‐art review of evidence and challenges

Investigating Individual Pre-trauma Susceptibility to a PTSD-Like Phenotype in Animals

Prevention and treatment of PTSD: the current evidence base

Inflammation and post‐traumatic stress disorder

Animal models of post-traumatic stress disorder and novel treatment targets

Innate and adaptive immune system consequences of post-traumatic stress disorder

Latest developments in post-traumatic stress disorder: diagnosis and treatment

Mechanisms of developing post-traumatic stress disorder: new targets for drug development and other potential interventions

Clinical potential of epigenetic and microRNA biomarkers in PTSD